Literature DB >> 18070122

Role of CD10 immunochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver.

A Ahuja1, N Gupta, N Kalra, R Srinivasan, Y Chawla, A Rajwanshi.   

Abstract

BACKGROUND: Differentiation of hepatocellular carcinoma (HCC) from metastatic carcinoma in liver may be difficult on fine needle aspiration cytology (FNAC), especially when both appear as moderate to poorly differentiated tumours. A panel of immunocytochemical stains is frequently used in case of diagnostic difficulty. Recently, CD10 immunostain with a canalicular staining pattern has been shown to be a specific marker for hepatocytic differentiation.
OBJECTIVE: The present study was designed to assess the value of CD10 immunostain in distinguishing HCC from metastatic carcinoma in material obtained by FNAC of liver masses.
MATERIALS AND METHODS: Formalin-fixed, paraffin-embedded cell blocks of 22 cases (7 cases of HCC and 15 cases of metastatic carcinoma), direct acetone-fixed smears and destained smears of 28 cases (18 cases of HCC and 10 cases of metastatic carcinoma) prepared from FNAC of the liver were immunostained using monoclonal antibody against CD10.
RESULTS: Seventeen (68%) of twenty-five cases of HCC were positive for CD10 with a canalicular staining pattern. Among them 7 (70%) of 10 cases were well-differentiated HCC and 10 (66%) of 15 cases were moderate to poorly differentiated HCC. Of 25 cases of metastatic carcinoma, four (16%) were positive for CD10 with a cytoplasmic (three cases) and membranous staining (one case) pattern.
CONCLUSION: CD10 immunostaining is useful in discriminating HCC and metastatic carcinoma of the liver and is easily applied on cell blocks as well as FNAC smears.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18070122     DOI: 10.1111/j.1365-2303.2007.00520.x

Source DB:  PubMed          Journal:  Cytopathology        ISSN: 0956-5507            Impact factor:   2.073


  4 in total

1.  Candidate biomarkers in exosome-like vesicles purified from rat and mouse urine samples.

Authors:  Javier Conde-Vancells; Eva Rodriguez-Suarez; Esperanza Gonzalez; Agustin Berisa; David Gil; Nieves Embade; Mikel Valle; Zigmund Luka; Felix Elortza; Conrad Wagner; Shelly C Lu; Jose M Mato; M Falcon-Perez
Journal:  Proteomics Clin Appl       Date:  2010-04       Impact factor: 3.494

Review 2.  The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations.

Authors:  Ashish Kumar; Subrat K Acharya; Shivaram P Singh; Vivek A Saraswat; Anil Arora; Ajay Duseja; Mahesh K Goenka; Deepali Jain; Premashish Kar; Manoj Kumar; Vinay Kumaran; Kunisshery M Mohandas; Dipanjan Panda; Shashi B Paul; Jeyamani Ramachandran; Hariharan Ramesh; Padaki N Rao; Samir R Shah; Hanish Sharma; Ragesh B Thandassery
Journal:  J Clin Exp Hepatol       Date:  2014-05-22

3.  Fine-needle aspiration biopsy of hepatocellular carcinoma and related hepatocellular nodular lesions in cirrhosis: controversies, challenges, and expectations.

Authors:  Aileen Wee
Journal:  Patholog Res Int       Date:  2011-06-30

Review 4.  Role of B Cell Development Marker CD10 in Cancer Progression and Prognosis.

Authors:  Deepshikha Mishra; Sunita Singh; Gopeshwar Narayan
Journal:  Mol Biol Int       Date:  2016-11-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.